Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.

There are currently no reliable, established serum biomarkers to predict the prognosis of radiotherapy for advanced cervical cancer. We aimed to identify serum biomarkers for survival after radiotherapy for cervical cancer. In this multicenter prospective cohort study, the usefulness of pre- and pos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoko Harima, Takuro Ariga, Yuko Kaneyasu, Hitoshi Ikushima, Sunao Tokumaru, Shigetoshi Shimamoto, Takeo Takahashi, Noriko Ii, Kayoko Tsujino, Anneyuko I Saito, Hiroki Ushijima, Takafumi Toita, Tatsuya Ohno
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/35fe0528408448aa868e60daef9e04e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:35fe0528408448aa868e60daef9e04e8
record_format	dspace
spelling	oai:doaj.org-article:35fe0528408448aa868e60daef9e04e82021-12-02T20:04:33ZClinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.1932-620310.1371/journal.pone.0259235https://doaj.org/article/35fe0528408448aa868e60daef9e04e82021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259235https://doaj.org/toc/1932-6203There are currently no reliable, established serum biomarkers to predict the prognosis of radiotherapy for advanced cervical cancer. We aimed to identify serum biomarkers for survival after radiotherapy for cervical cancer. In this multicenter prospective cohort study, the usefulness of pre- and posttreatment serum protein levels of potential biomarkers, including squamous cell carcinoma antigen (SCC-Ag), apolipoprotein C-II (ApoC-II), matrix metalloproteinase (MMP)1, and MMP2, were evaluated together with clinical factors in 145 cervical cancer patients in order to determine their suitability to predict survival. Progression-free survival (PFS) was the primary endpoint, and overall survival (OS), pelvic PFS (PPFS), and distant metastasis-free survival (DMFS) were the secondary endpoints. Blood samples were collected before and 1 month after radiotherapy to measure serum biomarker levels. ApoC-II was measured using a monoclonal antibody-based enzyme-linked immunosorbent assay, which was developed for this purpose. Kaplan-Meier method, log-rank test, and univariate and multivariate Cox proportional hazards models were used for statistical analyses. In multivariate analysis, larger tumor size was independently associated with shorter PFS, OS, PPFS, and DMFS, while longer overall treatment time was independently associated with shorter PPFS. Higher pretreatment SCC-Ag (P < 0.001) was associated with shorter DMFS. Higher posttreatment SCC-Ag (P = 0.017) was also associated with shorter DMFS. Pretreatment ApoC-II was associated with PPFS in univariate analysis (P = 0.048), but not in multivariate analysis. Patients with pretreatment ApoC-II levels ≤ 25.8 μg/ml had shorter PPFS than those with pretreatment ApoC-II levels > 25.8 μg/ml (P = 0.023, log-rank test). Pre- and posttreatment serum SCC-Ag and pretreatment serum ApoC-II levels may be important biomarkers to predict survival outcomes of patients with cervical cancer after radiotherapy. Pre- and posttreatment SCC-Ag and pretreatment ApoC-II might be useful in clinical settings for screening patients to improve treatment strategies in cervical cancer.Yoko HarimaTakuro ArigaYuko KaneyasuHitoshi IkushimaSunao TokumaruShigetoshi ShimamotoTakeo TakahashiNoriko IiKayoko TsujinoAnneyuko I SaitoHiroki UshijimaTakafumi ToitaTatsuya OhnoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0259235 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yoko Harima Takuro Ariga Yuko Kaneyasu Hitoshi Ikushima Sunao Tokumaru Shigetoshi Shimamoto Takeo Takahashi Noriko Ii Kayoko Tsujino Anneyuko I Saito Hiroki Ushijima Takafumi Toita Tatsuya Ohno Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.
description	There are currently no reliable, established serum biomarkers to predict the prognosis of radiotherapy for advanced cervical cancer. We aimed to identify serum biomarkers for survival after radiotherapy for cervical cancer. In this multicenter prospective cohort study, the usefulness of pre- and posttreatment serum protein levels of potential biomarkers, including squamous cell carcinoma antigen (SCC-Ag), apolipoprotein C-II (ApoC-II), matrix metalloproteinase (MMP)1, and MMP2, were evaluated together with clinical factors in 145 cervical cancer patients in order to determine their suitability to predict survival. Progression-free survival (PFS) was the primary endpoint, and overall survival (OS), pelvic PFS (PPFS), and distant metastasis-free survival (DMFS) were the secondary endpoints. Blood samples were collected before and 1 month after radiotherapy to measure serum biomarker levels. ApoC-II was measured using a monoclonal antibody-based enzyme-linked immunosorbent assay, which was developed for this purpose. Kaplan-Meier method, log-rank test, and univariate and multivariate Cox proportional hazards models were used for statistical analyses. In multivariate analysis, larger tumor size was independently associated with shorter PFS, OS, PPFS, and DMFS, while longer overall treatment time was independently associated with shorter PPFS. Higher pretreatment SCC-Ag (P < 0.001) was associated with shorter DMFS. Higher posttreatment SCC-Ag (P = 0.017) was also associated with shorter DMFS. Pretreatment ApoC-II was associated with PPFS in univariate analysis (P = 0.048), but not in multivariate analysis. Patients with pretreatment ApoC-II levels ≤ 25.8 μg/ml had shorter PPFS than those with pretreatment ApoC-II levels > 25.8 μg/ml (P = 0.023, log-rank test). Pre- and posttreatment serum SCC-Ag and pretreatment serum ApoC-II levels may be important biomarkers to predict survival outcomes of patients with cervical cancer after radiotherapy. Pre- and posttreatment SCC-Ag and pretreatment ApoC-II might be useful in clinical settings for screening patients to improve treatment strategies in cervical cancer.
format	article
author	Yoko Harima Takuro Ariga Yuko Kaneyasu Hitoshi Ikushima Sunao Tokumaru Shigetoshi Shimamoto Takeo Takahashi Noriko Ii Kayoko Tsujino Anneyuko I Saito Hiroki Ushijima Takafumi Toita Tatsuya Ohno
author_facet	Yoko Harima Takuro Ariga Yuko Kaneyasu Hitoshi Ikushima Sunao Tokumaru Shigetoshi Shimamoto Takeo Takahashi Noriko Ii Kayoko Tsujino Anneyuko I Saito Hiroki Ushijima Takafumi Toita Tatsuya Ohno
author_sort	Yoko Harima
title	Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.
title_short	Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.
title_full	Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.
title_fullStr	Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.
title_full_unstemmed	Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.
title_sort	clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein c-ii in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: a multicenter prospective cohort study.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/35fe0528408448aa868e60daef9e04e8
work_keys_str_mv	AT yokoharima clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT takuroariga clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT yukokaneyasu clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT hitoshiikushima clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT sunaotokumaru clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT shigetoshishimamoto clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT takeotakahashi clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT norikoii clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT kayokotsujino clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT anneyukoisaito clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT hirokiushijima clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT takafumitoita clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy AT tatsuyaohno clinicalvalueofserumbiomarkerssquamouscellcarcinomaantigenandapolipoproteinciiinfollowupofpatientswithlocallyadvancedcervicalsquamouscellcarcinomatreatedwithradiationamulticenterprospectivecohortstudy
_version_	1718375532889899008

Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.

Ejemplares similares